Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
schizophrenia
Biotech
CNS biotech attempts to break the IPO ice
The CNS company needs cash badly, with only $14 million in the bank as of June 30, plus an accumulated deficit of $114 million.
Gabrielle Masson
Aug 25, 2025 11:10am
Atai's schizophrenia drug fails to improve cognition in phase 2
Jul 28, 2025 7:45am
What were the biggest clinical trial flops of 2024?
Feb 21, 2025 9:00am
2024's top 10 clinical trial flops
Feb 18, 2025 3:00am
Boehringer's schizophrenia drug fails trio of phase 3 trials
Jan 16, 2025 11:58am
Phase 2 schizophrenia fails will cost AbbVie about $3.5B
Jan 10, 2025 11:06am
